Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3681]

ASH 2010: Bortezomib in the treatment of lymphoma

ASH 2010: Bortezomib in the treatment of lymphoma

ASH 2010: Bortezomib in the treatment of multiple myeloma

ASH 2010: Bortezomib in the treatment of multiple myeloma

ASH 2010: DASISION and OPTIM trial data for Dasatinib

ASH 2010: DASISION and OPTIM trial data for Dasatinib

$ASH: Ofatumumab offer hope for patients with fludarabine-refractory chronic lymphocytic leukaemia$

ASH: Ofatumumab offer hope for patients with fludarabine-refractory chronic lymphocytic leukaemia

SABCS 2010: Exemestane another possible first-line adjuvant therapy for hormone-receptor positive, early stage breast cancer

SABCS 2010: Exemestane another possible first-line adjuvant therapy for hormone-receptor positive, early stage...

SABCS 2010: Oestrogen alone effective for reducing breast cancer risk

SABCS 2010: Oestrogen alone effective for reducing breast cancer risk

SABCS 2010: Zoledronic acid breast cancer disappointment

SABCS 2010: Zoledronic acid breast cancer disappointment

Genome-wide association scans identify genetic loci associated with renal cancer and neoroblastoma susceptibility

Genome-wide association scans identify genetic loci associated with renal cancer and neoroblastoma susceptibility

Treatment of the elderly population with haematological cancers: What's new from the American Society of Hematology 2010 meeting?

Treatment of the elderly population with haematological cancers: What's new from the American Society of...

Mechanism that controls cell movement linked to tumours becoming more aggressive

Mechanism that controls cell movement linked to tumours becoming more aggressive

More from ecancer